RxDoctor Payments Data

Joseph Ceravolo, MD

Ophthalmology · Columbus, GANPI 1508857038

Payments from drug & device makers

$5,991in general payments, 2019–2025

Across 224 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson Surgical Vision, Inc.$934
  • Glaukos Corporation$729
  • ANI Pharmaceuticals, Inc.$508
  • Sun Pharmaceutical Industries Inc.$445
  • Amgen$423
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$5,90599%
  • Education$180%
  • Gifts$451%
  • Entertainment$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,991 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$215,220
Medicare patients
486
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost80$41,680
RestasisCyclosporine27$21,786
CombiganBrimonidine Tartrate/Timolol52$12,901
Alphagan PBrimonidine Tartrate38$8,942
Prednisolone Acetate209$7,093
Brimonidine Tartrate112$5,558
Ketorolac Tromethamine205$4,626
MoxifloxacinMoxifloxacin Hcl140$3,487
Cyclosporine17$3,180
Acetazolamide40$1,538
Latanoprost105$1,243
Doxycycline Hyclate18$578
Dorzolamide Hcl25$433
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$309
Ofloxacin14$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,697$85,308197 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →